Eli Lilly and Company Stock News

Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer's treatment Kisunla, which recently was approved in the U.S.

Money has poured into the sector as markets have grown concerned about the economy.

Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.

The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland.  The pharmaceutical giant is spending $1 billion to expand an existing site in Limerick Ireland, to increase the production of certain active ingredients, including those used in its Alzheimer's treatment Kis...

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS , Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of bio...

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.